e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

58.54 +0.05 (+0.09%)

Official Closing Price Updated: 7:00 PM EST, Feb 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

44 45 Next >

My 3 Biggest Stock Market Predictions for March ↗

February 21, 2023

These three trends will likely drive revenue and share prices.

Via The Motley Fool

EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue ↗

February 15, 2023

Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among...

Via Benzinga

JNJ Terminates NASH Program Pact With Arrowhead Pharmaceuticals ↗

February 15, 2023

Via Benzinga

Vir Biotech To Work On Next-Gen COVID-19 Solutions Independently, Or With Other Partners, As GSK Walks Out ↗

February 14, 2023

Vir Biotechnology Inc (NASDAQ: VIR) has amended the research collaboration agreement established with GSK plc (NYSE: GSK) in 2020.

Via Benzinga

GSK CEO Emma Walmsley On Beating Q4 Earnings ↗

February 01, 2023

GSK came out with quarterly earnings of $0.64 per share.

Via Talk Markets

GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine ↗

February 01, 2023

Via Benzinga

Preview: GlaxoSmithKline's Earnings ↗

January 31, 2023

Via Benzinga

Earnings Preview: GSK Q4 Earnings Expected To Decline ↗

January 25, 2023

This drug developer is expected to post quarterly earnings of $0.59 per share in its upcoming report, which represents a year-over-year change of -31.4%.

Via Talk Markets

Dividend Income Update For January 2023 ↗

February 12, 2023

Without rehashing the wild ride we experienced in the market over the last few months, I could find comfort in one thing: my dividends (even if dividend cuts are on the table these days). Let's see how...

Via Talk Markets

Week In Review: CANbridge In-Licenses Gene Therapy For Rare Disease From UMass ↗

February 11, 2023

CANbridge Pharma exercised an option for global rights to a novel second-gen gene therapy from UMass Chan medical school. Additionally, Zhimeng Biopharma signed an agreement to out-license global...

Via Talk Markets

FDA AdComm Votes In Favor Of GSK's Jemperli Single Arm Trial Plan For Rectal Cancer Setting ↗

February 10, 2023

Via Benzinga

FDA Grants Complete Approval For GSK's Jemperli For Endometrial Cancer ↗

February 10, 2023

Via Benzinga

Is Biotech Immunocore About To Make A 25% Price Move?

February 07, 2023

Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.

Via MarketBeat

Topics ETFs

GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

January 23, 2023

Via Benzinga

February 2023 Stock Considerations ↗

February 05, 2023

With a new trading month already in full swing, it is time to highlight some of my potential stock purchases. While the market had a nice bounce in recent months, there is still no shortage of stocks...

Via Talk Markets

Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review ↗

February 03, 2023

The major indexes continued to run despite mixed-to-weak earnings.

Via Investor's Business Daily

FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease ↗

February 02, 2023

Via Benzinga

Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report ↗

February 01, 2023

Two of the three companies easily beat sales and earnings expectations, but sales fell for the third.

Via Investor's Business Daily

Earnings Scheduled For February 1, 2023 ↗

February 01, 2023

Companies Reporting Before The Bell • Novo Nordisk (NYSE:NVO) is expected to report quarterly earnings at $0.85 per share on revenue of $6.84 billion.

Via Benzinga

February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More ↗

January 31, 2023

The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...

Via Benzinga

CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs ↗

January 30, 2023

Via Benzinga

The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK ↗

January 30, 2023

But Moderna stock didn't move higher on the announcement.

Via Investor's Business Daily

How Could GSK's RSV Vaccine Change its Valuation?

January 26, 2023

GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.

Via MarketBeat

3 Penny Stocks That Could Make You Filthy Rich ↗

January 25, 2023

These low-priced equities could deliver enormous returns for risk-tolerant shareholders.

Via The Motley Fool

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering ↗

January 24, 2023

Via Benzinga

COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock ↗

January 21, 2023

Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.

Via The Motley Fool

Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review ↗

January 20, 2023

Microsoft and Google are slashing jobs. Netflix and Tesla jumped.

Via Investor's Business Daily

Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market ↗

January 19, 2023

After years of lab failures, the companies could crack open a multibillion-dollar market.

Via Investor's Business Daily

Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy' ↗

January 18, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Biohaven Ltd (NYSE: BHVN) is a "great speculative buy."

Via Benzinga

Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today ↗

January 18, 2023

Moderna, Inc. (NASDAQ: MRNA) shares were solidly higher in premarket trading on Wednesday.

Via Benzinga

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

44 45 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy